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Aim. Out study aimed to assess the serum levels of adipokines in patients with peripheral arterial occlusive disease (PAOD) caused
by atherosclerosis. Methods. Serum samples were obtained from 221 patients. One hundred and forty patients, (26 females and
114 males) met the inclusion criteria and were assigned into the case group. Eighty one patients (17 females and 64 males), were
included in the control group. Circulating plasma levels of adiponectin, leptin, resistin, and TNF-α were measured using the
enzyme-linked immunosorbent assay (ELISA) method. Results. Signiﬁcant lower levels of adiponectin were present (P = 0.0061)
in PAOD patients (2380.23±1634.42pg/mL) compared to the control group (3065.06±1901.2pg/mL). The mean value of leptin
(2844.42 ± 3301.08pg/mL) and resistin (2047.81±3301.08pg/mL) patients included in the PAOD group was higher, as compared
to the control group. Statistically signiﬁcant diﬀerence was found between the two groups for leptin (P = 0.0332) and for resistin
(P = 0.0352). No statistically signiﬁcant diﬀerence for TNF-α was found between the two groups (P>0.05). Conclusion.T h e
markers of inﬂammation secreted by the adipose tissue (adiponectin, leptin, resistin) showed signiﬁcant diﬀerences in patients
from the case group (with PAOD) compared to the control group.
1.Introduction
Atherosclerosisistheprimarycauseofcoronaryheartdisease
(CHD) and of peripheral arterial occlusive disease (PAOD),
being one of the most common causes for disease and death
throughout the world [1]. It has been found that the adipose
tissue is connected with the pathogenesis of atherosclerosis
as a result of a secretion of a multitude of pro- and antiather-
ogenic cytokines and adipokines such as adiponectin, leptin,
resistin, and acute-phase proteins [2]. These adipokines play
a central role in the pathogeny of the metabolic syndrome [3,
4] and in the development of systemic inﬂammation [5, 6].
The serum levels of adiponectin, potential mediator of
atherosclerosis, are signiﬁcantly low in the case of patients
with visceral obesity and insulin-resistance as well as in the
case of type 2 diabetes mellitus [4, 6, 7]. The low levels of
adiponectin were associated with the presence of CHD [6, 8]
and appear to be a risk factor for CHD [6, 9].
Besides adiponectin, the adipokines intensely produced
bytheadiposetissueareleptinandresistin.Thephysiological
role of leptin is very complex; it could be an important medi-
ator of the relationship among obesity, overweight, and ath-
erosclerosis [3, 5]. Resistin, also involved in endothelial dys-
function, expressed primarily in inﬂammatory cells, suggests
a potential role in atherosclerosis [10, 11]. However, the re-
lationship between resistin and inﬂammation, insulin resis-
tance, and atherosclerosis in humans remains unexplored.
Tumor necrosis factor-α (TNF-α), a pleiotropic proinﬂam-
matory cytokine, has been also recognized in human athe-
roma [12].
Adiponectin, leptin, and resistin are adipocytokines that
control body weight, and insulin sensitivity [13]. These
adipokines have been investigated in relation to obesity, met-
abolic syndrome, insulin resistance, and other pathological
conditions and processes. In addition, it is now established
that adipokines play a role in the maintenance of an inﬂam-
matory state in adipose tissue and in the development of
obesity and comorbidities [14].
It has become increasingly evident that white adipose
tissue-derived cytokines mediate between obesity-related2 Mediators of Inﬂammation
exogenous factors and the molecular events that lead to
metabolic syndrome, inﬂammation, and cardiovascular dis-
eases [15]. Although there are studies which demonstrate the
relationship between adipokines, obesity, and increased risk
ofcardiovascularevents[14–16],theirinterplayisstillpoorly
studied.
The hypothesis of the study starts from the assumption
that among people aged over 55 atherosclerotic PAOD is
a known indicator of systemic atherosclerotic disease [17]
and literature in this area is scarce [18–20]. The role of
adiponectin in the initiation and development of atheroscle-
rotic lesions in PAOD patients has been studied and analyzed
very little so far [21]. At the same time remains unexplored
the role of leptin and resistin in PAOD. In the absence of
data on relationship between adipokines and atherosclerotic
PAOD, we have decided to undertake the present study.
The aim of our study was to assess the serum levels of
adipokines (adiponectin, leptin, resistin, and TNF-α)i np a -
tients with PAOD caused by atherosclerosis. Furthermore,
the link between serum levels within investigated adipokines
on one hand and between adipokines and cholesterol, HDL
cholesterol, triglycerides, glycemia, ﬁbrinogen, or CRP (C
reactive protein), smoking, obesity, arterial hypertension,
type II diabetes mellitus, coronary heart disease on the other
hand was investigated.
2.MaterialsandMethods
2.1. Study Protocol. A prospective case-control study was
carriedoutattheSurgicalClinic No. 2oftheCounty Clinical
Hospital of Cluj-Napoca, Romania, from January 2009 to
January 2011.
The case group included patients with PAOD caused by
atherosclerosis, diagnosed by duplex scanning, based on an
ankle-brachial index (ABI) < 0.9. The ankle-brachial index
was calculated by dividing the ankle systolic pressure mea-
sured at the malleolar level with a blood pressure cuﬀ, to the
higher of the two brachial pressures.
Patients with terminal diseases (e.g., cardiovascular fail-
ure,hepaticorrenalfailure,etc.)wereexcludedfromthecase
group. Only the patients who agreed to participate in the
study were included.
The control group included matched patients from our
outpatients referred to us for lower limb chronic venous in-
sufﬁciency problems, general surgery conditions (e.g., ap-
pendicitis, hernia, cholecystitis, etc.), or hospital staﬀ and
their relatives that presented an ABI > 0.9. The subjects
includedinthisgrouphadnoknownhistoryofautoimmune
diseases, neoplasia, cardiovascular failure, and hepatic or
renal failure.
The study was approved by the Local Ethics Commit-
tee (both University’s and Hospital’s) and was conducted
according to the Helsinki Declaration of 1964 as revised in
1983. Each subject included in the study (both case and
control group) signed a written informed consent for their
participation in the study. All subjects participated voluntary
and the conﬁdentiality of all data was respected.
The following data were collected for both groups: meas-
urementsofbasicconstituents(age,weight,height,anddistal
arterial pressures), medical history (arterial hypertension
(AHT), type II diabetes mellitus (DM), coronary heart dis-
ease (CHD)), and drug use (e.g., actual or former smoking
habit—more than 10 cigarettes/day and alcohol abuse).
From each subject included in the study, we obtained a
blood sample and determined the following parameters:
cholesterol, triglycerides, ﬁbrinogen, high-density lipoprote-
in (HDL), glycemia, creatinine, adiponectin, leptin, resistin,
TNF-α, and C reactive protein (CRP). To all subjects includ-
ed in the study the blood samples were collected after an
overnight fast, in the morning between 7 and 9 AM. Plasma
concentrationsofglucose,creatinine,lipids,andlipoproteins
were determined using standard enzymatic colorimetric
methods. Normal serum concentration of CRP was consid-
ered normal at values lower than 1mg/dL. Total cholesterol
> 200mg/dL was used as a cutoﬀ value for the lipid proﬁle
according to Adult Treatment Panel III guidelines [22].
Circulating plasma levels of adiponectin, leptin, resistin
and TNF-α were measured by a commercially available en-
zyme-linked immunosorbent assay (ELISA), using Quantik-
ine reagents (R&D Systems): Human Adiponectin, Human
Leptin, Human Resistin, and Human TNF-α/TNFSF1A.
Body mass index (BMI) was calculated according to
Quetelet’s formula: weight (kg)/height (m2)[ 23]. The fol-
lowing classiﬁcation of subjects according to BMI was ap-
plied to both case and control group: BMI < 25kg/m2 =
normal, 25 ≤ BMI < 30kg/m2 = overweight, and BMI ≥
30kg/m2 = obese (over 40, morbidly obese). Patients were
considered as hypertensive according to Joint British Soci-
eties’ guidelines, patients with systolic blood pressure higher
than 140mmHg or with diastolic blood pressure higher than
90mmHg, or both [24]. Coronary heart disease (CHD) was
deﬁned by standard Framingham Heart Study criteria as
any of new-onset angina, coronary insuﬃciency, or fatal or
nonfatal myocardial infarction [25]. Diabetes mellitus (DM)
was deﬁned according to the American Diabetes Association
as follows: any patient with two fasting plasma glucose levels
of 126mg/dL (7.0mmol/L) or higher, or treatment with
blood glucose-lowering drugs [26].
2.2. Statistical Analysis. Descriptive statistics for quantitative
data were expressed as mean, standard deviation, and 95%
conﬁdence intervals whenever the data were normal dis-
tributed. Otherwise, the median was used. The comparisons
between groups for quantitative data were carried out
with Student’s t-test when data were normally distributed;
otherwise the Mann-Withney test was applied.
Qualitative variables were summarized as absolute fre-
quency,percentagesandassociated95%conﬁdenceintervals.
The 95% conﬁdence interval was calculated based on opti-
mized binomial distribution formula [27, 28]. Comparison
between two proportions was performed by applying the Z-
test. Statistical analysis was carried out with SPSS v. 16; all
tests were applied at a signiﬁcance level of 5%.
The link between the investigated adipokines and choles-
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CRP was investigated using Pearson correlation coeﬃcient
if experimental data proved to be normally distributed;
otherwise Spearman correlation coeﬃcient was used. The
link between the investigated adipokines and the qualitative
variables (such as obesity, AHT (yes/no), DM (yes/no), CHD
(yes/no), and smoking (yes/no)) was carried out by applying
theSpearman’srankcorrelationcoeﬃcient.Thepowerofthe
correlation was interpreted according to Colton rules [29]. A
correlation coeﬃcient was considered statistically signiﬁcant
when the P value was smaller than 0.05.
3. Results
3.1. Studied Groups. One hundred and forty patients, 26
females (18.6%, 95%CI (12%–26%)) and 114 males (81.4%,
95%CI (74%–88%)), met the inclusion criteria and were
studied in the case group. Eighty-one patients, 17 females
(21%, 95%CI (12%–31%)) and 64 males (79%, 95%CI
(69%–88%)), were included in the control group. No
statistically signiﬁcant diﬀerence was identiﬁed between the
proportion of females in both case and control group (P =
0.6647).
The mean age in the case group was of 65.25 ± 10.84
years (95%CI (63.44–67.06)), with a median of 65.50. A
statistically signiﬁcant age diﬀerence was identiﬁed between
the female patients (70.35 ± 10.33, 95%CI (66.18–74.52),
median = 72) and the male patients (64.09 ± 10.66, 95%CI
(62.11–66.07)) in the case group (Mann-Withney statistics =
989, P = 0.0082).
The mean age of control group was of 60.83±10.60 years
(95% CI (58.48–63.17)), with a median of 60. No statistically
signiﬁcant age diﬀerence was identiﬁed between the female
population (65.06±10.87, 95%CI (59.47–70.650), median =
68) and the male population (59.70 ± 10.33, 95%CI (57.12–
62.28)) in the controlgroup (Mann-Whitney statistics = 412,
P = 0.1258).
A statistically signiﬁcant diﬀerence regarding the age of
the subjects in the case and control group was identiﬁed
(Mann-Whitney statistics = 4320, P = 0.0032).
The mean of BMI of case group was of 26.54 ± 4.58
(n = 140); the mean of BMI of control group was of 26.23 ±
4.64. No statistically signiﬁcance diﬀerence regarding the
BMI between the case and the control group was identiﬁed
(Student’s t-test = 0.483, df (degrees of freedom) = 219, P
value = 0.629).
3.2. Case versus Control Comparison. The comparison be-
tween case and control featuring number of patients, per-
centages, and associated Z-scores considering associated dis-
eases is presented in Table 1.
The biochemical characteristics of both case and control
group are presented in Table 2.
The serum levels of the inﬂammation parameters syn-
thesized by the adipose tissue determined by the described
immunological techniques are presented in Table 3.
Adiponectin presented statistically signiﬁcant (P =
0.0061, Table 3) lower levels in PAOD patients (2380.23 ±
1634.42pg/mL) than in control group patients (3065.06 ±
Table 1: Associated diseases: comparison between case and control
group.
Group Z-test to compare
proportions
Casean (%) Controlbn (%) ZP value
Obesity 33 (23.57) 24 (29.63) −0.9613 0.3364
DM 45 (32.14) 27 (33.33) −0.1528 0.8786
AHT 95 (67.86) 39 (48.15) 2.9374 0.0033
CHD 106 (75.71) 31 (38.27) 5.8555 <0.0001
Smoking status 97 (69.29) 45 (55.56) 1.9231 0.0545
asample size case group = 140 patients; bsample size control group =
81 subjects; DM: Diabetes mellitus; AHT: arterial hypertension; CHD:
coronary heart disease.
1901.2pg/mL). The serum levels of leptin, resistin, and CRP
proved to be also statistically signiﬁcant higher in the case
group compared to the control group (P<0.05, Table 3).
The serum levels of leptin and resistin were also moni-
tored, levels which had higher mean values in PAOD patients
compared to control group patients, hence the statistically
signiﬁcant diﬀerences (Table 3).
TNF-αdidnotpresentsigniﬁcantdiﬀerencesbetweenthe
two investigated groups (Table 3).
The graphical representation of the ranges associated to
the markers of the inﬂammation secreted by the adipose
tissue is presented in Figures 1(a)–1(d).
Eighty patients (24 from case group and 65 from control
group) had the TNF-α over the normal value. Out of these
patients, almost 73% were normal weighted or overweighed,
27% were obese.
The correlation analysis carried out on adipokines iden-
tiﬁed the following statistically signiﬁcant correlations; the
results are presented in Table 4.
All other correlations within adipokines and between
adipokines and all investigated variables did not prove to be
statistically signiﬁcant (P>0.05).
4. Discussion
The levels of adipokines (adiponectin, leptin, resistin, and
TNF-α) in patients with PAOD caused by atherosclerosis
were successfully investigated. The group of PAOD patients
was compared to a control group. The sampling of the
patients in both case and control group was as accurate
as possible. Unfortunately, statistically signiﬁcant diﬀerences
were identiﬁed for the following variables: age, AHT, and
CHD. The age of the patients in case and control group
provedtobeastatisticallysigniﬁcantdiﬀerence,butthisvari-
abledidnotaﬀecttheresultsofourstudysinceinthemedical
specialty literature no statistically signiﬁcant diﬀerence in
adipokineslevelwasreported[30].Nostatisticallysigniﬁcant
diﬀerence was identiﬁed between the two studied groups
for BMI. The presence of a statistically signiﬁcant diﬀerence
between groups in terms of BMI could be considered a bias
factor since the medical specialty literature proved an inverse
correlation between adiponectin and fat mass [31].4 Mediators of Inﬂammation
Table 2: Biochemical data for PAOD patients and controls.
Group Mann-Whitney test
Case Control Statistics P value
Cholesterol
(mg/dL)
Mean ± StDev 201.54 ±49.23 189.48 ±55.12 4869 0.0803
Median 193.00 190.00
TG (mg/dL) Mean ± StDev 130.62 ±56.97 116.81 ±52.01 4769 0.0490
Median 117.00 105.00
HDL (mg/dL) Mean ± StDev 48.23 ±13.01 46.65 ±11.57 5295 0.4120
Median 48.00 46.00
Creatinine
(mg/dL)
Mean ± StDev 0.89 ±0.21 0.84 ±0.21 4829 0.0614
Median 0.90 0.90
Glycemia (mg/dL) Mean 99.97 ±22.63 98.32 ±18.04 5494 0.7006
Median 94.00 95.00
Fibrinogen
(mg/dL)
Mean 341.66 ±84.07 318.68 ±72.20 4725 0.0390
Median 338.00 311.00
TG: triglycerides; HDL: high-density lipoprotein; StDev: Standard deviation.
Table 3: Serum concentrations of the studied parameters in the diﬀerent studied groups.
Group Mann-Whitney test
Case Control Statistics P value
Adiponectin
(pg/mL)
Mean ± StDev 2380.23 ±1634.42 3065.06 ±1901.2 4415 0.0061
Median 2170.00 2536.00
Leptin (pg/mL) Mean ± StDev 2844.42 ±3301.08 2047.81 ±3301.08 4695 0.0332
Median 1515.00 1254.00
Resistin (pg/mL) Mean ± StDev 16.14 ±10.68 13.84 ±11.20 4706 0.0352
Median 13.75 12.00
TNF-α (pg/mL) Mean ± StDev 4.96 ±5.18 5.11 ±6.01 5540 0.7756
Median 3.30 2.90
CRP (mg/dL) Mean ± StDev 0.82 ±0.45 0.62 ±0.41 4131 0.0008
Median 0.80 0.50
TNF-α: tumor necrosis factor-α; CRP: C reactive protein; StDev: standard deviation.
The absence of a statistically signiﬁcant diﬀerence in the
proportion of genders between groups proves the proper
assignment of patients in the groups. A higher statistically
signiﬁcant proportion of patients from our case group
proved to have had AHT compared to control group (P<
0.05, see Table 1)[ 32]. Moreover, a higher statistically
signiﬁcantproportionofpatientsfromthecasegroupproved
to have had CHD compared to the control group (P<0.05,
see Table 1)[ 11, 32–34].
The absence of a statistically signiﬁcant diﬀerence
between the percentages of diabetes mellitus in both case
and control groups conﬁrms the reliability of our results,
knowing that this disease is an important risk factor for large
vesselatheroscleroticocclusivedisease[10,32].Furthermore,
even if smoking was identiﬁed as being closely linked to
PAOD, a relation ﬁrst identiﬁed by Erb in 1911 [34–36],
the distribution of smoking in our group’s patients did not
prove to be statistically signiﬁcant diﬀerent (P = 0.0545, see
Table 1). The groups under investigation were homogeneous
as far as the demographic data and clinical characteristics
wereconcerned,exceptfortheagevariableandtheassociated
cardiovascular diseases.
Hyperlipidemia has been associated with an increased
rateoflowerextremityocclusivedisease(P = 0.049,Table 2),
and our results were according to the data published by
the medical specialty literature [37]. Even if some studies
identiﬁed the cholesterol serum level as an important
independent risk factor, in our study it was not associated
with PAOD [36].
No statistically signiﬁcant diﬀerences could be identiﬁed
for cholesterol, HDL, Creatinine, and glucose serum levels
(Table 2).
The ﬁbrinogen proved to be statistically diﬀerent in our
study when the two investigated groups were compared
(higher values in the case group compared to control group,
P<0.05, see Table 2).
Another acute phase protein, CRP, which normally
increases not only in infections but also in activations of
certain chronic diseases, was also signiﬁcantly higher in the
investigated PAOD patients (P<0.05, Table 3).Mediators of Inﬂammation 5
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Figure 1: The graphic representation of the serum levels ranges of the inﬂammation markers (adipokines, CRP) in the PAOD patients and
the control group.
In our study the serum values of adiponectin were sig-
nificantly lower in the case group than the values of the
control group (Table 3). This result could indicate that hy-
poadiponectinemia is related to the development of PAOD.
Since that low levels of adiponectin are correlated to
endothelial dysfunction [38], the results of our study suggest
that hypoadiponectinemia can be used as a marker of
atherosclerosis. Because almost a third of patients included
in the study were obese or diabetic, further studies on larger
sample size must be carried out for the association between
adipokines and CRP and PAOD in the nonobese/diabetic
population.
With regard to the role of leptin in the development
of atherosclerotic lesions in PAOD, our study has indi-
cated signiﬁcantly increased serum levels in these patients
compared to control group (P<0.05, Table 3). Knowing
its proatherogenic function, correlated with the increased
values that we had detected, recommends this parameter
as a possible biomarker of atherosclerosis with peripheral
vascular localizations [39–41].6 Mediators of Inﬂammation
Table 4: The results of correlation analysis.
Variables
Correlation
Direction Power P value
Case group
TNF-α versus DM Positive Weak 0.0341
Resistin versus AHT Negative Weak 0.0080
Adiponectin versus AHT Positive Weak 0.0313
Leptin versus cholesterol Positive Weak 0.0437
Leptin versus triglycerides Positive Weak 0.0090
Control group
TNF-α versus obesity Negative Week 0.0468
TNF-α versus adiponectin Negative Weak 0.0222
TNF-α versus leptin Positive Weak 0.0255
Leptin versus triglycerides Negative Weak 0.0238
Adiponectin versus AHT Negative Weak 0.0359
Obesity versus HDL cholesterol Positive Week 0.0342
Week correlation was considered whenever the correlation coeﬃcient was
between [−0.5; 0.5].
Themeanvaluesofresistinpresentedsigniﬁcantlyhigher
valuesinPAODpatientscomparedtothepatientsinthecon-
trolgroup,andthisfactsuggesteditspossibleparticipationin
the process of atherogenesis (P<0.05, Table 3). As far as we
know there are no published data available to appreciate the
role of resistin in the case of PAOD; therefore more studies
are required.
A series of positive or negative signiﬁcant correlations
were identiﬁed between certain adipokines and some of the
investigated parameters (see Table 4) but all these correla-
tions proved to be weak. Leptin proved to be signiﬁcantly
relatedwithtriglycerideserumlevel,positivelyforcasegroup
and negatively for control group. Adiponectin proved to be
signiﬁcantly related with AHT, positively for case group and
negatively for control group. In our study, adipokine levels
did not prove to be related to obesity or to BMI, a fact
contradicted by some studies [31]. Adiponectin and leptin
proved to be signiﬁcantly related to TNF-α in control group
and obesity was also related to TNF-α (Table 4), conﬁrming
data from the literature [7, 8, 42].
T h ew e a kn e g a t i v er e l a t i o n s h i p( P<0.05, Table 4)
between TNF-α and adiponectin conﬁrmed the already
known antagonistic eﬀect of the adiponectin on the TNF-α
activity [43–46].
Study Strengths and Limitations. Adipokines expression has
been extensively studied in cardiovascular disease but all
studies have been performed either on patients with typical
ischaemic heart disease or in hypertensive patients [10–12,
15]. However, except for a recent report by Dieplinger et al.
[21], there had been no other data on adipokines expression
in PAOD. More important, Dieplinger et al. [21] studied
only adiponectin expression in PAOD and the results are
similartoourﬁndings.Thisisapilotstudydesignedtoassess
if inﬂammatory and metabolic mediators can be used as
potentialatheroscleroticbiomarkersinPAODpatients.Here,
we have showed that serum adiponectin, resistin, and leptin
might have a potential role in developing atherosclerotic
lesions in patients with PAOD. Further experimental and
clinical studies are required to establish the exact role of
adipokines in the disease development and to provide a
deﬁnite answer to the question of whether measuring these
chemokines could be used for the follow-up of PAOD
patients.
5. Conclusion
The markers of the inﬂammation secreted by the adipose
tissue (adiponectin, leptin, resistin, CRP) showed signiﬁcant
diﬀerences in case group patients (with PAOD) compared
to control group. Our results point out the possible role
of hypoadiponectinemia in developing PAOD. Proinﬂam-
matory cytokines produced by white adipose tissue (resistin
and leptin) are likely to be promising targets for controlling
the reduction of inﬂammation in order to prevent the
progression of early or already established atherosclerotic
lesions in PAOD patients, but further research is, however,
necessary.
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